(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 7 July 2005 (07.07.2005)

PCT

(10) International Publication Number WO 2005/060993 A1

- (51) International Patent Classification⁷: A61K 39/00, C07K 14/00, 14/025
- (21) International Application Number:

PCT/NL2003/000929

(22) International Filing Date:

24 December 2003 (24.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

- (71) Applicant (for all designated States except US): LEIDEN UNIVERSITY MEDICAL CENTER [NL/NL]; Albinusdreef 2, NL-2333 ZA Leiden (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): VAN DER BURG, Sjoerd, Hendrikus [NL/NL]; Schuberthof 15, NL-2742 BT Waddinxveen (NL). DRIJFHOUT, Jan, Wouter [NL/NL]; Da Costastraat 41, NL-2321 AK Leiden (NL).


- (74) Agents: VAN WESTENBRUGGE, Andries et al.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

[Continued on next page]

(54) Title: SYNTHETIC PROTEIN AS TUMOR-SPECIFIC VACCINE



MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPD RAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP

(3) HPV16-E7

(57) Abstract: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV proteins directed immunity as a model.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.